Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD

Bridevaux, P.-O.; Gerbase, M. W.; Probst-Hensch, N. M.; Schindler, C.; Gaspoz, J.-M.; Rochat, T.
September 2008
Thorax;Sep2008, Vol. 63 Issue 9, p768
Academic Journal
Background: Little is known about the long-term outcomes of individuals with mild chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Methods: A population cohort of 6671 randomly selected adults without asthma was stratified into categories of modified GOLD-defined COPD (prebronchodilator spirometry). Further stratification was based on the presence or absence of respiratory symptoms. After 11 years, associations between baseline categories of COPD and decline in forced expiratory volume in 1 s (FEV1), respiratory care utilisation and quality of life as measured by the SF-36 questionnaire were examined after controlling for age, sex, smoking and educational status. Results: At baseline, modified GOLD criteria were met by 610 (9.1%) participants, 519 (85.1%) of whom had stage 1 COPD. At follow-up, individuals with symptomatic stage 1 COPD (n = 224) had a faster decline in FEV1 (-9 ml/year (95% CI -13 to -5)), increased respiratory care utilisation (OR 1.6 (95% Cl 1.0 to 2.6)) and a lower quality of life than asymptomatic subjects with normal lung function (n = 3627, reference group). In contrast, individuals with asymptomatic stage 1 COPD (n = 295) had no significant differences in FEV1 decline (-3 mI/year (95% CI -7 to +1)), respiratory care utilisation (OR 1.05 (95% CI 0.63 to 1.73)) or quality of life scores compared with the reference group. Conclusions: In population-based studies, respiratory symptoms are of major importance for predicting long-term clinical outcomes in subjects with COPD with mild obstruction. Population studies based on spirometry only may misestimate the prevalence of clinically relevant COPD.


Related Articles

  • ABC of chronic obstructive pulmonary disease. Devereux, Graham // BMJ: British Medical Journal (International Edition);5/13/2006, Vol. 332 Issue 7550, p1142 

    The article focuses on several aspects of chronic obstructive pulmonary disease. The author cites the definition of the disease, its epidemiology, its morbidity impacts and mortality rates, and its risk factors. The author lists cigarette smoking as the single most important risk factor in...

  • Chronic obstructive pulmonary disease. Miles, Jon // GP: General Practitioner;2/2/2007, p40 

    The article presents information about chronic obstructive pulmonary disease (COPD). It is estimated that three million people have COPD, of whom just under one third may be accurately diagnosed. Exposure to cigarette smoke is the most important factor in the development of COPD. Cigarettes and...

  • Feasible and simple exclusion criteria for pulmonary reference populations. Johannessen, Ane; Omenaas, Ernst R.; Eide, Geir Egil; Bakke, Per S.; Gulsvik, Amund // Thorax;Sep2007, Vol. 62 Issue 9, p792 

    Background: International guidelines recommend that pulmonary reference populations consist of never-smokers without respiratory diseases or symptoms, but the diseases and symptoms are not clearly specified. The present study aimed to identify simple exclusion criteria for defining pulmonary...

  • Smoking, respiratory symptoms and likely asthma in young people: evidence from postal questionnaire surveys in the Wythenshawe Community Asthma Project (WYCAP). Frank, Peter; Morris, Julie; Hazell, Michelle; Linehan, Mary; Frank, Timothy // BMC Pulmonary Medicine;2006, Vol. 6, p10 

    Background: Although it is recognised that smoking is a major risk factor for subjects with chronic obstructive pulmonary disease and is associated with respiratory symptoms, there is less agreement concerning the relationship between asthma and smoking. This study aims to examine the...

  • Indoor exposures and respiratory symptoms in a Norwegian community sample. Skorge, T. Duelien; Gulsvik, A.; Bakke, P. S.; Eagan, T. M. L.; Eide, G. E. // Thorax;Nov2005, Vol. 60 Issue 11, p937 

    Background: Limited data are available on the effect of a poor indoor climate on the respiratory health of adults. No data are available regarding the contribution of indoor exposures to the burden of respiratory symptoms in the population. Methods: In 1996-7 a community sample of 3181 adults...

  • Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. Polosa, Riccardo; Morjaria, Jaymin Bhagwanji; Caponnetto, Pasquale; Prosperini, Umberto; Russo, Cristina; Pennisi, Alfio; Bruno, Cosimo Marcello // Respiratory Research;12/16/2016, Vol. 17, p1 

    Background: Electronic cigarettes (ECs) are battery-operated devices designed to vaporise nicotine, which may help smokers quitting or reducing their tobacco consumption. There is a lack of data on the health effects of EC use among smokers with COPD and whether regular use results in...

  • Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease. Güder, Gülmisal; Brenner, Susanne; Störk, Stefan; Held, Matthias; Broekhuizen, Berna D. L.; Lammers, Jan-Willem J.; Hoes, Arno W.; Rutten, Frans H. // BMC Pulmonary Medicine;Jul2015, Vol. 15 Issue 1, p1 

    Background: The maximal expiratory flow at 50 % of the forced vital capacity (MEF50) is the flow where half of forced vital capacity (FVC) remains to be exhaled. A reduced MEF50 has been suggested as a surrogate marker of small airways disease. The diagnostic and prognostic utility of this easy...

  • Serum levels and genotype distribution of α1-antitrypsin in the general population. Ilaria Ferrarotti; Gian Andri Thun; Michele Zorzetto; Stefania Ottaviani; Medea Imboden; Christian Schindler; Arnold von Eckardstein; Lucia Rohrer; Thierry Rochat; Erich W Russi; Nicole M Probst-Hensch; Maurizio Luisetti // Thorax;Aug2012, Vol. 67 Issue 8, p669 

    Rationaleα1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges...

  • Suppression of NLRX1 in chronic obstructive pulmonary disease. Min-Jong Kang; Chang Min Yoon; Bo Hye Kim; Chang-Min Lee; Yang Zhou; Sauler, Maor; Homer, Rober; Dhamija, Anish; Boffa, Daniel; West, Andrew Phillip; Shadel, Gerald S.; Ting, Jenny P.; Tedrow, John R.; Kaminski, Naftali; Woo Jin Kim; Chun Geun Lee; Yeon-Mok Oh; Elias, Jack A. // Journal of Clinical Investigation;Jun2015, Vol. 125 Issue 6, p2458 

    Cigarette smoke (CS) and viruses promote the inflammation and remodeling associated with chronic obstructive pulmonary disease (COPD). The MAVS/RIG-I-like helicase (MAVS/RLH) pathway and inflammasome-dependent innate immune pathways are important mediators of these responses. At baseline, the...


Read the Article


Sign out of this library

Other Topics